论文部分内容阅读
目的探讨胰腺癌患者血清可溶性Apo1/Fas(sApo1/Fas)水平的变化,以及化疗对血清sApo1/Fas的影响。方法采用酶联免疫吸附试验(ELISA)检测并比较58例胰腺癌患者和30例正常人的血清sApo1/Fas水平,比较48例胰腺癌患者化疗前后血清sApo1/Fas水平。结果胰腺癌患者血清sApo1/Fas为(8.37±1.49)ng/L,明显高于正常对照组(P<0.01)。胰腺癌患者血清sApo1/Fas水平与临床分期有关,Ⅳ期胰腺癌血清sApo1/Fas水平明显高于其他各期(P<0.01),Ⅲ期明显高于Ⅱ期(P<0.01);与胰腺癌患者的性别、年龄、病理类型无关。近期有效(完全缓解和部分缓解)的患者化疗前后血清sApo1/Fas分别为(8.07±1.54)ng/L和(7.39±1.49)ng/L,化疗后血清sApo1/Fas水平低于化疗前(P<0.01)。结论血清sApo1/Fas水平可能与胰腺癌的病情发展有关,血清sApo1/Fas检测对胰腺癌的疗效观察、病情监测及预后判断有重要的参考意义。
Objective To investigate the changes of serum soluble Apo1 / Fas (sApo1 / Fas) in patients with pancreatic cancer and the effects of chemotherapy on serum sApo1 / Fas. Methods Serum levels of sApo1 / Fas in 58 patients with pancreatic cancer and 30 normal individuals were detected by enzyme-linked immunosorbent assay (ELISA). Serum levels of sApo1 / Fas in 48 patients with pancreatic cancer were compared before and after chemotherapy. Results Serum sApo1 / Fas levels in pancreatic cancer patients were (8.37 ± 1.49) ng / L, which were significantly higher than those in normal controls (P <0.01). Serum levels of sApo1 / Fas in patients with pancreatic cancer were related to clinical stage. Serum sApo1 / Fas levels in patients with stage Ⅳ pancreatic cancer were significantly higher than those in other stages (P <0.01), and stage Ⅲ were significantly higher than those in stage Ⅱ (P <0.01) The patient’s gender, age, pathological type has nothing to do. The serum levels of sApo1 / Fas in the patients who were recently effective (complete remission and partial remission) were (8.07 ± 1.54) ng / L and (7.39 ± 1.49) ng / L respectively before and after chemotherapy and were lower than those before chemotherapy <0.01). Conclusions Serum sApo1 / Fas levels may be related to the development of pancreatic cancer. The detection of serum sApo1 / Fas in pancreatic cancer has important reference value in the observation of the curative effect, disease monitoring and prognosis.